Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer


Eight patients affected by non-small-cell lung cancer were treated with intralesional and systemic recombinant IL-2(rIL-2) injection with the aim of activating both tumour-infiltrating lymphocytes and circulating cytotoxic or killer cells. The schedule of treatment was as follows: a daily fine-needle transparietal intralesional rIL-2 injection (1×105 Cetus… (More)
DOI: 10.1007/BF01517044


5 Figures and Tables